An interventional study of moderate statin dose and high dose statin in Statin Dose, sponsored by Shiraz University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 52 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-11.
Sponsored by Shiraz University of Medical Sciences · Not applicable, Interventional, and Treatment
In this study post coronary stenting patients, were enrolled to receive moderate dose versus high dose statin for 1 year, and the result of major adverse cardiovascular events were recorded
In this randomized double-blind clinical trial, the study population was all patients with a recent history of PCI who referred to the professor kojuri cardiovascular clinic for the first post-procedure visit. In the first visit, patients were randomly divided into two groups Both groups were treated with Rosuvastatin 40 mg as high potency statin for one month after PCI. In the first group, after one month, the statin level changed to Rosuvastatin 5 mg daily (moderate intensity). In the second group, 40 mg of Rosuvastatin was continued for one year. Then, the participants were evaluated in terms of MACEs, including any hospitalization due to acute coronary syndrome, as well as history of stroke and myocardial Infarction, subsequent unplanned revascularization and cardiac death. The HS-CRP also checked between two groups
Shiraz University of Medical Sciences is the lead sponsor of 129 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients 1 month post PCI, allocated to 5 mg rosuvastatin per day
Drug: moderate statin dose
patients 1 month post PCI, allocated to 40 mg rosuvastatin
Drug: high dose statin
5 mg rosuvastatin per day
40 mg rosuvastatin per day
major adverse cardiovascular events (MACE)
major adverse cardiovascular events
Time frame: 1 year
serum level of HS-CRP
Time frame: 1 year
Plan to share: No — Dat available on demand of reviewer
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shiraz University of Medical Sciences